PALYNZIQ REMS
What is the PALYNZIQ® (pegvaliase-pqpz) Injection Risk Evaluation and Mitigation Strategy (REMS)?
- A REMS is required by the FDA to ensure that the benefits of therapy outweigh the risks
- The goal of the PALYNZIQ REMS is to mitigate the risk of anaphylaxis1

Enroll yourself
- Read the full Prescribing Information for PALYNZIQ
- Read the REMS Prescriber Guide
- Read the REMS Program Overview
- Complete the REMS Prescriber Knowledge Assessment
- Sign the REMS Prescriber Enrollment Form

Enroll each patient
- Counsel your patient on the risks associated with PALYNZIQ, including the risk of anaphylaxis and the need for auto-injectable epinephrine
- Prescribe auto-injectible epinephrine, and instruct patients how to use it and to carry it with them at all times
- Review the following with your patient:
- REMS Patient Guide
- REMS Wallet Card
- REMS Safety Video
- You and your patient must sign the REMS Patient Enrollment Form
Visit PALYNZIQREMS.com or submit signed, completed forms by fax or mail to the PALYNZIQ REMS:
Phone:
Fax:
PALYNZIQ REMS, 200 Pinecrest Plaza, Morgantown, WV 26505
Reference: 1. PALYNZIQ [package insert]. Novato, CA: BioMarin Pharmaceutical Inc; 2018.